Efficacy and safety results from GEICO 1205, a randomized phase II trial of neoadjuvant chemotherapy with or without bevacizumab for advanced epithelial ovarian cancer

Yolanda Garcia Garcia; Ana de Juan Ferré; Cesar Mendiola; Maria-Pilar Barretina-Ginesta; Lydia Gaba Garcia; Ana Santaballa Bertrán; Isabel Bover Barcelo; Marta Gil-Martin; Aranzazu Manzano; Maria Jesús Rubio Pérez; Margarita Romeo Marin; Cristina Arqueros Núñez; Elena García-Martínez; Antonio Gonzalez Martin

doi:10.1136/ijgc-2019-000256

Subscribe
Log In More

Log in via Institution
Log in via OpenAthens
Log in via your Society

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Close More
Main menu

Latest content

Current issue

Archive

Authors

About

YouTube

Podcasts

Zoom Journal Club
Subscribe
Log in More

Log in via Institution
Log in via OpenAthens
Log in via your Society

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
BMJ Journals

Alerts

Original Article

Efficacy and safety results from GEICO 1205, a randomized phase II trial of neoadjuvant chemotherapy with or without bevacizumab for advanced epithelial ovarian cancer

Log in using your username and password

Main menu

Log in using your username and password

You are here

Read the full text or download the PDF:

Log in using your username and password